InnoPharmax (4172) Stock Overview

InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company's core products include N11005, a prandial oral insulin and GemOral. Its core technology is OralPAS Pro platform, a solid-SMEDDS dosage form composed of peptide drug, solvent, co-solvent, and surfactant adsorbed onto granules by inert excipients. The company offers anti-infection agents, including Bestnem, an imipenem and cilastatin sodium solution that is used intravenous in the treatment of various infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, or bone and joint infections; and various complicated or uncomplicated urinary tract infections, septicemia, or endocarditis caused by susceptible organisms. It also provides contrast agents consisting of gadopentetate dimeglumine and gadodiamide. In addition, the company offers oncology agents comprising Innomustine and Immurin; and Inpheno tablets for rare diseases. The company was founded in 2005 and is based in Taipei City, Taiwan. InnoPharmax Inc. is a subsidiary of Synmosa Biopharma Corporation.